Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.

News

17 December 2021

Our 3rd Newsletter is out

Scroll through the QSPainRelief December 2021 Newsletter to learn about the project’s progress, highlights and outcomes of the 3rd GA Meeting, two new Masterclasses, upcoming events, and new team- and SEAB-members. We are also updating you on Bachelor students’ projects conducted for QSPainRelief in Prof. Dr. Liesbeth de Lange’s group at ULEI and clarify that all 2020 registrations for the Quantitative Systems Pharmacology Conference are valid for QSPC2022 – the replacement date next year in Leiden, The Netherlands, from 20 – 22 April 2022.

More news

Events

24 - 25 May 2022

6th SC Meeting in Munich

Welcome to Munich, QSPainRelief Steering Committee (SC) members and researchers! The concentris team is looking forward to seeing you all in person and learning about the newest research results and project developments. The meeting starts at noon on Tuesday, May 24th, featuring summary presentations of all scientific work packages (WP2-WP8) on the first afternoon, followed by presentations on management, dissemination, and ethics (WP1, WP9, and WP10) as well as an Impact & Innovation Board (IIB) discussion on Wednesday morning, May 25th.

More events
Personalise and maximize pain relief for individuals suffering from chronic pain

Summary Statement

10 institutions in Europe and the USA collaborate for the next 5 years to help patients suffering from chronic pain. QSPainRelief aims to develop effective drug combination treatments for the improved relief of chronic pain. A quantitative systems pharmacology (QSP) mathematical modelling approach will be used to identify and validate more effective therapeutic interventions by smart combinations of existing drugs. The ultimate goal is to personalise and maximize pain relief for individuals suffering from chronic pain while diminishing side effects.

Learn more

Objectives

  • Consolidating cutting-edge treatment models for chronic pain
  • Summary Statement
  • Validating novel combinational therapies preclinically in vitro and in vivo
  • Conducting clinical studies to detect functional biomarkers
  • Improving the clinical guidelines for pain relief in stratified patient groups
  • Personalising pain relief treatment for each patient
  • Improving the scientific understanding of chronic pain regarding age, sex, disease and genetic factors

Impact

  • Novel concepts of combinational pain relief therapies
  • Improved efficacy and acceptability in the clinic
  • Effective stratification of patients with respect to age, sex, disease and genotype
  • Personalised treatment with unswerving benefits for patients
  • Unique knowledge gain and innovation opportunities